The overall pooled odds ratio for development of CIN using a fixed-effects model was 0.62 (95% CI, 0.37 to 1.03, P = 0.06), suggesting a trend towards a reduction in CIN with ACE inhibitors. The gene discussed is ACE; the disease is cervical squamous intraepithelial neoplasia.